Digitisation | April 04, 2024
Aurigene introduces AI/ML assisted drug discovery platform
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Aurigene.AI is an end-to-end solution for small molecule drug discovery
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)